ALK and large cell neuroendocrine carcinoma: Given the patients with ALK rearrangement-positive LCNEC may obtain increased benefit from ALK inhibitors than conventional chemotherapies, clinicians should routinely test for ALK rearrangement in patients with LCNEC.